Quinazoline-2-Carboxamides as Selective PET Radiotracers for Matrix Metalloproteinase-13 Imaging in Atherosclerosis
Journal of Medicinal Chemistry · 25.05.2023 · 66 (10) · 6682-6696
DOI: 10.1021/acs.jmedchem.2c02107 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 09.05.2023. Verfasst von Ariel Buchler und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, Ontario K1N 9B4, Canada. Hauptthemen laut MEDLINE: Plaque, Atherosclerotic, Atherosclerosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: CIHR, University of Ottawa Heart Institute Foundation, University of Ottawa.
Abstract (Originalsprache)
Matrix metalloproteinase-13 (MMP-13) plays a critical role in the progression of unstable atherosclerosis. A series of highly potent and selective MMP-13 inhibitors were synthesized around a quinazoline-2-carboxamide scaffold to facilitate radiolabeling with fluorine-18 or carbon-11 positron-emitting nuclides and visualization of atherosclerotic plaques. In vitro enzyme inhibition assays identified three compounds as promising radiotracer candidates. Efficient automated radiosyntheses provided [11C]5b, [11C]5f, and [18F]5j and enabled pharmacokinetic characterization in atherosclerotic mice. The radiotracers displayed substantial differences in their distribution and excretion. Most favorably for vascular imaging, [18F]5j exhibited low uptake in metabolic organs with minimal retention of myocardial radioactivity, substantial renal clearance, and high metabolic stability in plasma. Ex vivo aortic autoradiography and competition studies revealed that [18F]5j specifically binds to MMP-13 within atherosclerotic plaques and localizes to lipid-rich regions. This study demonstrates the utility of the quinazoline-2-carboxamide scaffold for MMP-13 selective positron emission tomography (PET) radiotracer development and identifies [18F]5j for imaging atherosclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, Ontario K1N 9B4, Canada.
- University of Ottawa Heart Institute, Ottawa, Ontario K1Y 4W7, Canada.
- Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada.
ORCID-Profile: Ariel Buchler, Myriam Adi, Jeffrey W Keillor, Benjamin H Rotstein
Förderung
- CIHR
- University of Ottawa Heart Institute Foundation
- University of Ottawa
- Canada Foundation for Innovation
- Institute of Circulatory and Respiratory Health
- Natural Sciences and Engineering Research Council of Canada
- Ontario Ministry of Research, Innovation and Science
Zitieren
APA
Buchler, A., Ismailani, U. S., MacMullin, N., Abdirahman, F., Adi, M., Bi, C., Jany, C., Keillor, J. W., & Rotstein, B. H. (2023). Quinazoline-2-Carboxamides as Selective PET Radiotracers for Matrix Metalloproteinase-13 Imaging in Atherosclerosis. Journal of Medicinal Chemistry, 66(10), 6682-6696. https://doi.org/10.1021/acs.jmedchem.2c02107
Vancouver
Buchler A, Ismailani US, MacMullin N, Abdirahman F, Adi M, Bi C, et al. Quinazoline-2-Carboxamides as Selective PET Radiotracers for Matrix Metalloproteinase-13 Imaging in Atherosclerosis. Journal of Medicinal Chemistry. 2023;66(10):6682-6696. doi:10.1021/acs.jmedchem.2c02107
BibTeX
@article{Buchler2023,
author = {Buchler, Ariel and Ismailani, Uzair S and MacMullin, Nicole and Abdirahman, Faduma and Adi, Myriam and Bi, Christina and Jany, Catherine and Keillor, Jeffrey W and Rotstein, Benjamin H},
title = {Quinazoline-2-Carboxamides as Selective PET Radiotracers for Matrix Metalloproteinase-13 Imaging in Atherosclerosis},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {10},
pages = {6682--6696},
doi = {10.1021/acs.jmedchem.2c02107}
}
EUVIMED